|
1 kits (10 Vials)
| Yawan: | |
|---|---|
▎ Tsarin Semaglutid
Source: Pub Chem |
Jerin: His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-lys (Aeea-Aeea-γ-glu-octadecanedioic)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH Tsarin kwayoyin halitta: C 187H 291N 45O59 Nauyin Kwayoyin: 4114 g/mol Lambar CAS 910463-68-2 Farashin 56843331 Ma'ana: Rybelsus; Ozempic ; Wegovy |
▎ Binciken Semaglutid
Menene asalin bincike na Semaglutid?
Ci gaban Semaglutid ya samo asali ne daga binciken abubuwan GLP-1 na ilimin lissafi. Masana kimiyya sun yi wahayi zuwa ga exendin-4 a cikin lizard salva don haɓaka agonist mai karɓa na farko na GLP-1. Don biyan zaɓin magani mai tsayi, Semaglutid an haɓaka ta hanyar gyaran sinadarai na sarkar peptide GLP-1, tare da ƙari na sarƙoƙi na fatty acid don tsawaita rabin rayuwarsa. Yayin da bincike ya ci gaba, yuwuwar sa a cikin asarar nauyi da rigakafin cututtukan zuciya da jiyya shima ya bayyana.
Menene tsarin aikin Semaglutid?
Dokokin insulin da kuma fitar da glucagon:
A matsayin GLP-1 agonist mai karɓa (GLP-1 RA), Semaglutid yana ƙarfafa ƙwayoyin β-pancreatic don ɓoye insulin yayin da yake hana α-sel daga ɓoye glucagon. Bayan cin abinci, lokacin da matakan glucose na jini ya tashi, semaglutide yana ɗaure ga masu karɓar GLP-1, yana kunna hanyoyin siginar ƙasa don sa ƙwayoyin β su saki insulin, haɓaka haɓakar jiki da amfani da glucose, da rage matakan glucose na jini. Ta hanyar hana fitowar glucagon da rage fitowar glucose na hanta, yana ƙara daidaita matakan glucose na jini. A ƙarƙashin yanayin ilimin lissafi na al'ada, jiki yana kiyaye matakan glucose na jini ta hanyar daidaita ma'auni tsakanin insulin da glucagon. Semaglutid yana kwaikwayon tasirin GLP-1, yana inganta wannan tsarin tsari [1,2].
Hoto 1 Abubuwan da ke da alaƙa da ciwon sukari da kiba na GLP-1 [3].
Hanta na hanta gluconeogenesis:
Semaglutid yana hana tsarin gluconeogenesis na hanta. Gluconeogenesis ita ce hanyar da hanta ke samar da glucose a lokacin azumi ko jihohin yunwa, kiyaye kwanciyar hankali na glucose na jini lokacin da matakan glucose na jini ya yi ƙasa. Koyaya, a cikin yanayin cututtukan cututtuka irin su ciwon sukari, gluconeogenesis na iya zama mai aiki da yawa, yana haifar da haɓakar matakan glucose na jini. Semaglutid yana aiki akan hanyoyin siginar da suka dace don rage magana ko aiki na enzymes na gluconeogenesis, don haka rage yawan samar da glucose na hanta da kuma taimakawa cikin sarrafa glucose na jini [1].
Effects akan makamashi metabolism da ci:
Semaglutid yana da tasiri mai tasiri akan metabolism na makamashi da ci. Yana rage yawan kuzari, mai yuwuwa ta hanyar yin aiki akan tsarin juyayi na tsakiya don yin tasiri ga cibiyoyin sarrafa abinci, haifar da jin daɗin cikawa da rage cin abinci. Bugu da ƙari, Semaglutid yana da ƙarancin tasiri akan kashe kuzarin kuzari, da farko cimma ka'idojin nauyi ta hanyar rage yawan kuzari, wanda ke taimakawa a cikin asarar nauyi ga marasa lafiya masu kiba. A cikin gwaji, marasa lafiya da ke amfani da Semaglutid sukan bayar da rahoton rage yawan ci da asarar nauyi mai zuwa [1,4].
Hanyoyin da za a iya yin aiki a kan tsarin zuciya na zuciya: Semaglutid na iya yin tasiri mai tasiri akan tsarin zuciya da jijiyoyin jini ta hanyar hanyoyi masu yawa. A gefe guda, yana iya rage glucose na jini da nauyin jiki, ta haka ne ya rage lalacewar da ke haifar da cututtuka na rayuwa zuwa tsarin zuciya. A gefe guda, Semaglutid na iya yin aiki kai tsaye a kan kyallen takarda na zuciya, kamar ta hanyar inganta aikin endothelial na jijiyoyi, rage amsawar kumburi da damuwa na oxidative, daidaitawa atherosclerotic plaques, da kuma rage hadarin cututtukan zuciya. Bincike na Cigrovski ya nuna cewa Semaglutid na iya inganta aikin ƙwayoyin endothelial na jijiyoyin jini a cikin ɓoye nitric oxide, haɓaka vasodilation, da kare tsarin zuciya [5].
Tasirin kai tsaye akan aikin zuciya:
Binciken da aka yi kwanan nan ya gano cewa m bayyanar da Semaglutid zai iya haifar da kashi-dogara mai karfi tasiri inotropic inotropic tasiri a kan ɗan adam atrial trabeculae ba tare da kara hali ga arrhythmias. Wannan sakamako na iya fitowa daga ƙarar sarcoplasmic reticulum Ca2+ reuptake, inganta aikin atrial, kuma yana riƙe da tasiri mai kyau ga alamar cututtuka a cikin marasa lafiya na zuciya. A cikin gwaje-gwaje masu alaƙa, trabeculae na atrial da aka fallasa ga Semaglutid ya nuna ingantaccen ƙarfin kwangila ba tare da haɓaka arrhythmias ba [6].
Menene aikace-aikacen Semaglutid?
Don nau'in ciwon sukari na 2:
Ana amfani da Semaglutid don kula da nau'in ciwon sukari na 2. Ko ana gudanar da shi ta baki ko ta hanyar allurar subcutaneous, yana rage yawan haemoglobin A1c (HbA1c) yadda ya kamata [1].
Don maganin kiba:
Semaglutid yana nuna tasiri mai mahimmanci a cikin maganin kiba. Gwaje-gwaje na asibiti sun nuna cewa marasa lafiya masu kiba da aka yi musu magani tare da semaglutide suna fuskantar babban asarar nauyi, tare da rage girman kugu, ingantattun sigogin hawan jini, saukar da matakan HbA1c, da ingantaccen bayanan martaba (misali, rage jimlar cholesterol, low-density lipoprotein cholesterol, da triglycerides, da ƙara yawan lipoprotein cholesterol mai yawa). Sakamakon asarar nauyi ya fi na placebos da sauran magungunan asarar nauyi, saduwa da ka'idodin da EMA da FDA suka tsara don magungunan asarar nauyi, da kuma samar da sabon zaɓi na magani ga marasa lafiya masu kiba [1,2].
Rage haɗarin cututtukan zuciya:
Ga manya da nau'in ciwon sukari na 2 da sanannun cututtukan zuciya, Semaglutid na iya rage haɗarin cututtukan cututtukan zuciya. Nazarin irin su SUSTAIN 6 da gwaje-gwajen PIONEER 6 sun nuna rashin rashin ƙarfi da aminci na Semaglutid subcutaneous da na baka a cikin lafiyar zuciya, kuma gwajin SELECT ya kara tabbatar da fa'idodin da yake da shi wajen inganta sakamakon cututtukan zuciya, yana taimakawa wajen rage haɗarin cututtukan zuciya [1].
Tasirin kariya na koda:
A cikin samfurin linzamin kwamfuta na renal ischemia-reperfusion rauni, Semaglutid ya nuna tasirin kariya na koda. It reduces levels of inflammatory molecules such as tumor necrosis factor-α (TNF-α) and its receptor, interleukin-6 (IL-6), decreases F8 prostaglandin production, increases PI3K and AKT levels in renal tissue, and alleviates renal injury, suggesting that Semaglutid may have therapeutic potential for acute kidney injury [7].
Kammalawa
A matsayin GLP-1 agonist mai karɓa, Semaglutid yadda ya kamata yana sarrafa matakan glucose na jini a cikin marasa lafiya da nau'in ciwon sukari na 2 ta hanyar sarrafa insulin da glucagon secretion, hana gluconeogenesis na hanta, da kuma tasirin metabolism na makamashi da ci, yayin da yake rage nauyin jiki a cikin mutane masu kiba. Yana da tasirin kariya na zuciya, yana rage haɗarin cututtukan zuciya, kuma yana kare kodan. Yana da tasirin warkewa akan mummunan rauni na koda, nephropathy na ciwon sukari, da sauran cututtukan koda.
Game da Marubuci
Abubuwan da aka ambata a sama duk bincike ne, gyara su kuma Cocer Peptides ne suka haɗa su.
Mawallafin Jaridar Kimiyya
Hegner, P. yana dogara ne a Jami'ar Regensburg a Jamus kuma yana da fa'idodin bincike da yawa. Wadannan sun hada da tsarin zuciya da jijiyoyin jini, inda ya binciko hanyoyin da maganin cututtukan zuciya; Biochemistry da ilmin kwayoyin halitta, mai da hankali kan gano hanyoyin da ke tattare da kwayoyin halitta da na kwayoyin halitta da kuma tsarin gudanarwa; ilimin harhada magunguna da kantin magani, yana mai da hankali kan haɓakar magunguna da kimanta ingancin inganci; da tsarin numfashi da kuma magungunan gabaɗaya da na ciki, suna mai da hankali kan ganowa da kuma kula da cututtukan numfashi da yanayin kiwon lafiya na ciki na yau da kullun. Malami ne wanda ya samu nasarori a fannonin likitanci da dama. An jera Hegner P a cikin ambaton ambaton [6].
